May 14, 2020 / 9:55 PM / 16 days ago

BRIEF-NantKwest And ImmunityBio To Initiate Phase 2 Study Of Immunotherapy For Metastatic Pancreatic Cancer

May 14 (Reuters) - NantKwest Inc:

* NANTKWEST AND IMMUNITYBIO TO INITIATE A PHASE 2 STUDY OF IMMUNOTHERAPY FOR METASTATIC PANCREATIC CANCER

* NANTKWEST INC - STUDY HAS RECEIVED FDA AUTHORIZATION AND IS EXPECTED TO BEGIN IN JUNE 2020

* NANTKWEST INC - OPEN-LABEL, RANDOMIZED PHASE 2 STUDY WILL EVALUATE COMBINATION IMMUNOTHERAPY

* NANTKWEST INC - STUDY WILL INITIALLY ENROLL 268 SUBJECTS ACROSS BOTH COHORTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below